Essais liés13clinical trials
VilleChapel Hilllocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06899074

Ouvrir le site du centre

Essais cliniques associés

13
MoléculeIndication / populationPhaseNCTTitreStatut
Mycophenolate Mofetil Lupus Phase 2 NCT05538208 The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study RECRUITING
Low Dose Mesenchymal Stem Cells (MSCs) Lupus Phase 2 NCT02633163 Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE) COMPLETED
Direct cortical stimulation (DCS) Alpha Épilepsie Non applicable NCT06252532 Causal Role of Top-Down Theta Oscillations in Prioritization ENROLLING_BY_INVITATION
Omega-3 Supplementation for Pediatric Migraine Migraine Non applicable NCT06899074 Omega-3 Supplementation for Pediatric Migraine COMPLETED
ADAPT — Marine Lipids Ease Painful TMD Migraine Non applicable NCT07437313 ADAPT — Marine Lipids Ease Painful TMD NOT_YET_RECRUITING
5% lidocaine/5 mg/ml 0.02% estradiol compound cream Migraine Phase 2 NCT03844412 Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments COMPLETED
RE104 for Injection Sclérose latérale amyotrophique Phase 2 NCT07002034 RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses RECRUITING
Mycophenolate Mofetil Myasthénie À vérifier NCT03490539 PROMISE-MG — Disease-Modifying Treatments for Myasthenia Gravis COMPLETED
Litifilimab Lupus Phase 2/3 NCT05531565 AMETHYST — A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus ACTIVE_NOT_RECRUITING
zorevunersen Épilepsie Phase 3 NCT06872125 A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome RECRUITING
Efgartigimod IV Myasthénie Phase 2 NCT04833894 ADAPT Jr — Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis RECRUITING
Efgartigimod PH20 SC Myasthénie Phase 3 NCT06558279 ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis ACTIVE_NOT_RECRUITING
eculizumab Myasthénie Phase 2 NCT00727194 Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis TERMINATED